Moderna to pay Immatics up to $1.8B in cancer-drug deal

By The Boston Globe
| September 11, 2023

Moderna Inc. agreed to pay German biotechnology company Immatics NV as much as $1.8 billion in a broad-ranging, multiyear collaboration on developing cancer therapies using messenger RNA and other technologies.

Full story

#1

Recent research on Paxlovid shows there is "solid data on its effectiveness," a co-author of the study told HealthLeaders. ...

A new personal protective equipment manufacturing company is set to open in Cincinnati next year. ...